Thromboembolism Clinical Trial
Official title:
A Pilot Randomized Controlled Trial of Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery. The investigators hypothesize that among eligible individuals, at least 35% will enroll, undergo randomization, and complete the allocated treatment group.
Venous thromboembolism (VTE) is a major contributor to maternal morbidity and mortality. The first two weeks postpartum are the highest risk period for VTE during pregnancy and the postpartum period. Cesarean delivery is a known risk factor for VTE. In the United States, postpartum prophylaxis with low molecular weight heparin (e.g., enoxaparin) is commonly used during the first 10-14 days after delivery. Enoxaparin has not been demonstrated as an effective intervention to prevent postpartum VTE after cesarean delivery. Before larger scale studies may be completed, a better understanding of ability to randomize individuals to this intervention is needed. This study aims to evaluate the feasibility of randomizing individuals after cesarean delivery to the receipt of enoxaparin prophylaxis or no treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05794165 -
Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism
|
Phase 2 | |
| Active, not recruiting |
NCT05563883 -
Atrial Fibrillation and Cancer: a Nationwide French Cohort Study
|
||
| Terminated |
NCT02475187 -
Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture
|
||
| Recruiting |
NCT00982514 -
Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008
|
N/A | |
| Completed |
NCT01420809 -
Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection
|
N/A | |
| Terminated |
NCT00206089 -
Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events
|
Phase 3 | |
| Completed |
NCT00014352 -
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
|
Phase 2 | |
| Completed |
NCT00000614 -
Prevention of Recurrent Venous Thromboembolism (PREVENT)
|
Phase 3 | |
| Active, not recruiting |
NCT05656963 -
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
|
||
| Completed |
NCT04719182 -
Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
|
||
| Completed |
NCT02935751 -
Apixaban Discontinuation Prior to Major Surgery
|
||
| Terminated |
NCT02579122 -
REVIparin-BRIDging-in a General Practice Setting in GErmany
|
||
| Completed |
NCT01696760 -
Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
|
N/A | |
| Completed |
NCT00986154 -
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
|
Phase 3 | |
| Terminated |
NCT00662688 -
Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT00260988 -
A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery
|
Phase 2/Phase 3 | |
| Terminated |
NCT00031837 -
Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
|
Phase 3 | |
| Completed |
NCT03877770 -
DVT After Cardiac Procedure
|
||
| Completed |
NCT00024297 -
Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters
|
N/A | |
| Completed |
NCT04686981 -
Endovascular thromBectomy of Acute Mesentery Vessels Occlusion Hybrid With Emergent Laparoscopic Surgery
|